CYP 8.16% 22.5¢ cynata therapeutics limited

Ann: New Study to Investigate the High Potency of Cymerus MSCs, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,220 Posts.
    lightbulb Created with Sketch. 3900
    Recap:

    https://hotcopper.com.au/data/attachments/3870/3870759-1b3c49ff4fa99a8ebbd10f6593cf804f.jpg
    https://research.monash.edu/en/projects/evaluating-the-molecular-mechanisms-of-the-therapeutic-effects-of

    2 March 2021
    Dr. Kilian Kelly, Cynata’s Chief Operating Officer, said:
    “This new study with Professor Samuel follows his earlier investigations, which confirmed the potent antiinflammatory and anti-fibrotic effects of our Cymerus MSCs in several different studies in pre-clinical models of allergic and fibrotic diseases of the lung, such as asthma and IPF. Given the importance of gaining a clearer understanding of the molecular processes involved in these potentially clinically useful effects, we believe this further study will provide important insights as we move forward in parallel with our plans for a clinical trial in IPF.”

    7 September 2020
    Professor Samuel commented:
    “These results are extremely encouraging. While they are very consistent with our previous studies of these cells in a model of asthma, it was important to confirm that the potent anti-inflammatory and anti-fibrotic effects of Cymerus MSCs would be replicated in IPF, which is a disease with very different underlying pathophysiology. We look forward to publishing our results in a peer-reviewed journal in due course.”
    https://files.cynata.com/613/200907CymerusMSCsEffectiveinPreclinicalLungDiseaseStudy.pdf


    https://hotcopper.com.au/data/attachments/3870/3870802-daeef4a30aaac3a607799ccf0ac96f62.jpg
    [...]

    https://hotcopper.com.au/data/attachments/3870/3870808-3c5e5e10bbe3e1cf56135551b7b8d39f.jpg
    https://www.eurekalert.org/news-releases/936666


    "We also found ubiquitous deposits of collagen, the main component of scar tissue."
    It might be worthwhole also checking our first pre-clinical Asthma study here:
    "IN delivery of Cymerus™ MSCs completely reversed pathologic collagen deposition in thelungs to levels seen in animals in which the asthma model was not induced. Pathologiccollagen deposition is a sign of airway remodelling/fibrosis. Previous studies by the samegroup found that IN administration of other types of stem cells did not have similar effects,unless used in combination with other drugs."
    http://files.cynata.com/279/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal.pdf

    I have summarised our Asthma studies here:
    https://hotcopper.com.au/threads/ann-further-cynata-asthma-study-published.4649689/page-13?post_id=37560912


    See here for my previous coverage on IPF/COVID-19:
    https://hotcopper.com.au/threads/ann-ethics-approval-to-commence-clinical-trial-in-covid-19.5386633/page-180?post_id=45798738


    Hopefully we get the final pre-clinical IPF study results ("Finished") soon!
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
-0.020(8.16%)
Mkt cap ! $40.68M
Open High Low Value Volume
24.5¢ 24.5¢ 22.5¢ $32.92K 143.1K

Buyers (Bids)

No. Vol. Price($)
1 21235 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 17528 1
View Market Depth
Last trade - 16.10pm 18/11/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.